Divi's Laboratories (DIVISLAB.NS) Stock Price

Divi's Laboratories Price

NSE·CLOSED
8,457.00INR-143.00 (-1.68 %)
Market closed

Over the last 19 years Divi's Laboratories grew revenue by 18.4% annually, reaching 93.60 B INR. Earnings per share have grown at 19.8% per year over the last 19 years. For Divi's Laboratories, the net margin of 23.4% is down versus 28.5% a few years ago. At today's price the dividend yield works out to roughly 0.35%. The payout ratio is around 36% of earnings. The dividend has grown at 6.0% per year over the past 19 years. The consensus 12-month price target for Divi's Laboratories is 7,012.50 INR, about 17.1% below where the stock trades today. Of 36 analysts, 20 rate the stock a buy — an overall Buy consensus. The stock trades about 49% above its 52-week low.

Divi's Laboratories stock price

Volume
Ex-Dividend
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Divi's Laboratories over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Divi's Laboratories stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Divi's Laboratories's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Divi's Laboratories Stock Price History
DateDivi's Laboratories Price
8/13/20268,457.00 INR
8/12/20268,600.00 INR
8/11/20268,578.50 INR
8/10/20268,300.00 INR
8/7/20268,275.00 INR
8/6/20268,349.00 INR
8/5/20268,388.00 INR
8/4/20268,266.00 INR
7/31/20268,056.00 INR
7/30/20267,814.00 INR
7/28/20267,460.00 INR
7/27/20267,414.00 INR
7/24/20267,248.50 INR
7/23/20267,301.00 INR
7/22/20267,386.50 INR
7/21/20267,330.00 INR
7/20/20267,318.00 INR
7/17/20267,249.50 INR
7/15/20267,273.00 INR
7/14/20267,188.50 INR
7/13/20266,938.50 INR
7/10/20266,836.00 INR
7/9/20266,813.00 INR
7/8/20266,755.00 INR
7/7/20266,771.50 INR
7/6/20266,857.50 INR
7/3/20266,756.50 INR
7/2/20266,682.50 INR
7/1/20266,545.50 INR
6/30/20266,579.00 INR
6/29/20266,557.50 INR
6/25/20266,713.50 INR
6/24/20266,753.50 INR
6/23/20266,747.00 INR
6/22/20266,787.50 INR
6/19/20266,743.00 INR
6/18/20266,767.00 INR
6/17/20266,663.50 INR
6/16/20266,712.50 INR
6/15/20266,628.00 INR
6/12/20266,638.00 INR
6/11/20266,655.50 INR
6/10/20266,771.00 INR
6/9/20266,753.00 INR
6/8/20266,521.00 INR
6/5/20266,623.00 INR
6/4/20266,596.50 INR
6/3/20266,576.50 INR
6/2/20266,533.00 INR
6/1/20266,553.50 INR
5/29/20266,667.00 INR
5/27/20266,797.50 INR
5/26/20266,753.00 INR
5/25/20266,756.50 INR
5/22/20266,887.00 INR
5/21/20266,858.00 INR
5/20/20266,929.00 INR
5/19/20266,912.00 INR
5/18/20266,835.00 INR
5/15/20266,760.50 INR
5/14/20266,921.50 INR
5/13/20266,796.00 INR
5/12/20266,644.00 INR
5/11/20266,714.00 INR
5/8/20266,710.50 INR
5/7/20266,702.50 INR
5/6/20266,702.00 INR
5/5/20266,651.00 INR
5/4/20266,619.50 INR
4/30/20266,502.50 INR
4/29/20266,534.00 INR
4/28/20266,432.50 INR
4/27/20266,477.00 INR
4/24/20266,361.50 INR
4/23/20266,378.50 INR
4/22/20266,285.50 INR
4/21/20266,286.00 INR
4/20/20266,280.00 INR
4/17/20266,229.00 INR
4/16/20266,293.50 INR
4/15/20266,177.50 INR
4/13/20266,070.00 INR
4/10/20266,116.50 INR
4/9/20265,952.50 INR
4/8/20265,882.00 INR
4/7/20265,850.00 INR
4/6/20265,821.00 INR
4/2/20265,856.50 INR
4/1/20265,905.00 INR
3/30/20265,960.00 INR
3/27/20265,997.50 INR
3/25/20266,015.00 INR
3/24/20266,020.00 INR
3/23/20266,015.00 INR
3/20/20266,101.00 INR
3/19/20265,998.00 INR
3/18/20266,124.00 INR
3/17/20266,090.00 INR
3/16/20266,066.50 INR
3/13/20266,070.00 INR
3/12/20266,285.50 INR
3/11/20266,330.00 INR
3/10/20266,379.00 INR
3/9/20266,333.50 INR
3/6/20266,325.00 INR
3/5/20266,364.50 INR
2/27/20266,395.50 INR
2/26/20266,474.00 INR
2/25/20266,387.50 INR
2/23/20266,258.50 INR
2/20/20266,292.00 INR
2/19/20266,275.00 INR
2/18/20266,283.50 INR
2/17/20266,195.00 INR
2/16/20266,120.00 INR
2/13/20266,177.00 INR
2/12/20266,185.00 INR
2/11/20266,394.50 INR
2/10/20266,175.50 INR
2/9/20266,113.50 INR
2/6/20266,025.00 INR
2/5/20266,141.50 INR
2/4/20266,060.00 INR
2/3/20266,209.00 INR
2/2/20265,968.50 INR
1/30/20266,025.50 INR
1/29/20266,040.00 INR
1/28/20266,188.00 INR
1/27/20266,055.00 INR
1/23/20266,009.50 INR
1/22/20266,071.00 INR
1/21/20266,010.00 INR
1/20/20266,013.00 INR
1/19/20266,140.00 INR
1/16/20266,236.00 INR
1/14/20266,355.50 INR
1/13/20266,436.50 INR
1/12/20266,485.50 INR
1/9/20266,616.50 INR
1/8/20266,608.00 INR
1/7/20266,647.00 INR
1/6/20266,651.00 INR
1/5/20266,348.50 INR
1/2/20266,392.50 INR
1/1/20266,346.00 INR
12/31/20256,398.00 INR
12/30/20256,480.50 INR
12/29/20256,410.00 INR
12/26/20256,427.50 INR
12/24/20256,494.00 INR
12/23/20256,480.00 INR
12/22/20256,511.50 INR
12/19/20256,460.00 INR
12/18/20256,380.00 INR
12/17/20256,290.00 INR
12/16/20256,333.50 INR
12/15/20256,365.00 INR
12/12/20256,419.00 INR
12/11/20256,422.00 INR
12/10/20256,306.00 INR
12/9/20256,272.00 INR
12/8/20256,327.00 INR
12/5/20256,486.00 INR
12/4/20256,420.00 INR
12/3/20256,460.00 INR
12/2/20256,401.50 INR
12/1/20256,419.50 INR
11/28/20256,461.50 INR
11/27/20256,499.00 INR
11/26/20256,510.00 INR
11/25/20256,410.00 INR
11/24/20256,359.00 INR
11/21/20256,360.00 INR
11/20/20256,470.00 INR
11/19/20256,443.00 INR
11/18/20256,470.50 INR
11/17/20256,546.00 INR
11/14/20256,511.50 INR
11/13/20256,593.50 INR
11/12/20256,520.00 INR
11/11/20256,528.00 INR
11/10/20256,691.50 INR
11/7/20256,656.50 INR
11/6/20256,875.00 INR
11/4/20256,818.00 INR
11/3/20256,791.00 INR
10/31/20256,750.00 INR
10/30/20256,645.00 INR
10/29/20256,508.50 INR
10/28/20256,430.00 INR
10/27/20256,490.00 INR
10/24/20256,610.00 INR
10/23/20256,572.00 INR
10/21/20256,587.00 INR
10/20/20256,604.00 INR
10/17/20256,621.50 INR
10/16/20256,584.50 INR
10/15/20256,556.00 INR
10/14/20256,561.00 INR
10/13/20256,565.00 INR
10/10/20256,489.00 INR
10/9/20256,123.50 INR
10/8/20256,106.00 INR
10/7/20256,104.50 INR
10/6/20255,816.00 INR
10/3/20255,851.50 INR
10/1/20255,710.50 INR
9/30/20255,692.00 INR
9/29/20255,697.50 INR
9/26/20255,689.50 INR
9/25/20255,897.00 INR
9/24/20255,978.00 INR
9/23/20256,038.50 INR
9/22/20256,092.00 INR
9/19/20256,200.00 INR
9/18/20256,112.00 INR
9/17/20256,054.00 INR
9/16/20256,084.50 INR
9/15/20256,053.00 INR
9/12/20256,022.00 INR
9/11/20256,025.00 INR
9/10/20256,031.50 INR
9/9/20256,005.00 INR
9/8/20256,031.50 INR
9/5/20256,020.00 INR
9/4/20256,130.00 INR
9/3/20256,170.50 INR
9/2/20256,119.00 INR
9/1/20256,090.00 INR
8/29/20256,095.00 INR
8/28/20256,132.00 INR
8/26/20256,190.50 INR
8/25/20256,242.00 INR
8/22/20256,151.50 INR
8/21/20256,030.00 INR
8/20/20256,005.00 INR
8/19/20256,079.50 INR
8/18/20256,154.50 INR
Access this data via the Eulerpool API
Get Free API Key

Divi's Laboratories Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2023
77.68 B INR
20.26 B INR
18.23 B INR
Jan 1, 2024
78.45 B INR
18.31 B INR
16.00 B INR
Jan 1, 2025
93.60 B INR
25.70 B INR
21.91 B INR
Jan 1, 2026 (e)
106.20 B INR
34.87 B INR
25.92 B INR
Jan 1, 2027 (e)
122.70 B INR
40.28 B INR
30.84 B INR
Jan 1, 2028 (e)
145.15 B INR
47.65 B INR
37.90 B INR
Jan 1, 2029 (e)
169.42 B INR
55.62 B INR
44.87 B INR
Jan 1, 2030 (e)
175.48 B INR
0.00 INR
0.00 INR

Divi's Laboratories Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 15, 2026, 12:42 PM
 
REVENUEB INR
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEB INR
EBITB INR
EBIT MARGIN%
NET INCOMEB INR
NET INCOME GROWTH%
DIV.INR
DIV. GROWTH%
SHARESM
201520162017201820192020202120222023202420252026e2027e2028e2029e2030e
31.1538.0541.0639.1349.4653.9469.6989.6077.6878.4593.60106.20122.70145.15169.42175.48
23.0222.157.92-4.7126.419.0629.2028.56-13.311.0019.3113.4715.5318.2916.723.58
53.6253.1854.9852.4556.3254.1460.5361.0652.5152.0853.5553.5553.5553.5553.5553.55
16.7020.2422.5820.5227.8629.2142.1954.7140.7940.8650.1256.8765.7077.7290.7293.97
10.3613.0413.6311.2617.0616.4026.1535.7320.2618.3125.7034.8740.2847.6555.62–
33.2734.2633.1928.7634.4830.4137.5239.8726.0823.3427.4632.8332.8332.8332.83–
8.5211.2610.608.7713.5313.7719.8429.6118.2316.0021.9125.9230.8437.9044.87–
10.1132.21-5.81-17.3054.241.7644.1649.20-38.41-12.2536.9418.3218.9422.9118.39–
20.0010.0010.0010.0016.0016.0020.0030.0030.0030.0030.0030.0030.0030.00––
–-50.00––60.00–25.0050.00––––––––
265.00265.00265.00265.00265.00265.00265.00265.00265.47265.47265.47265.47265.47265.47265.47265.47
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Divi's Laboratories generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Divi's Laboratories retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Divi's Laboratories's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Divi's Laboratories has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Divi's Laboratories's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Divi's Laboratories stock margins

The Divi's Laboratories margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Divi's Laboratories. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Divi's Laboratories.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2021
60.53 %
37.52 %
28.47 %
Jan 1, 2022
61.06 %
39.87 %
33.04 %
Jan 1, 2023
52.51 %
26.08 %
23.47 %
Jan 1, 2024
52.08 %
23.34 %
20.40 %
Jan 1, 2025
53.55 %
27.46 %
23.41 %
Jan 1, 2026 (e)
53.55 %
32.83 %
24.41 %
Jan 1, 2027 (e)
53.55 %
32.83 %
25.13 %
Jan 1, 2028 (e)
53.55 %
32.83 %
26.11 %

Divi's Laboratories Stock Revenue, EBIT, Earnings per Share

The Divi's Laboratories earnings per share therefore indicates how much revenue Divi's Laboratories has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2021
263.00 INR
98.67 INR
74.88 INR
Jan 1, 2022
338.11 INR
134.81 INR
111.72 INR
Jan 1, 2023
292.60 INR
76.31 INR
68.69 INR
Jan 1, 2024
295.52 INR
68.97 INR
60.27 INR
Jan 1, 2025
352.58 INR
96.81 INR
82.53 INR
Jan 1, 2026 (e)
400.06 INR
131.34 INR
97.66 INR
Jan 1, 2027 (e)
462.21 INR
151.74 INR
116.16 INR
Jan 1, 2028 (e)
546.75 INR
179.50 INR
142.77 INR

Divi's Laboratories business model & stock analysis

Divi's Laboratories Ltd. is a pharmaceutical company based in Hyderabad, India. It was founded in 1990 and has become one of the leading manufacturers of active ingredients and formulations for the pharmaceutical industry in recent years. The company was founded by Dr. Murali Divi, who built the company on principles of quality, technology, and innovation. Divi's Laboratories now employs approximately 13,000 employees and operates production facilities in India and the USA. The company operates in various sectors, including generics, custom synthesis, research and development, and nutraceuticals. Its products are used worldwide and are approved in over 95 countries. Divi's Laboratories follows a vertically integrated supply chain model, producing high-quality active ingredients and developing its own formulations for the pharmaceutical industry. The company always relies on innovative technologies and continuous improvement of product quality. Its product range includes a wide range of active ingredients for various therapeutic areas, such as antibiotics, antidepressants, antihypertensives, antidiabetics, static lipid-lowering agents, and antipsychotics. Divi's Laboratories has state-of-the-art production facilities, strict quality controls, and advanced analytical facilities for all pharmaceutical ingredients. In addition to its active ingredients, the company is also known for its custom synthesis services, which involve the production of customer-specific active ingredients for the pharmaceutical industry. Divi's Laboratories offers a tailored service that meets the specific requirements of customers, ranging from the development of new active ingredients and formulations to the production of small or medium quantities of active ingredients. In the area of research and development, Divi's Laboratories works closely with academic institutions and other pharmaceutical companies to leverage the latest scientific knowledge and develop innovative products. The company invests a significant sum in research and development annually. In addition to active ingredients and custom synthesis services, Divi's Laboratories also offers a range of nutraceuticals. These products, such as vitamins, minerals, and other dietary supplements, are used to support a healthy lifestyle. In summary, Divi's Laboratories is an India-based pharmaceutical company specializing in the manufacture of active ingredients and formulations for the pharmaceutical industry. The company operates to the highest quality standards and relies on innovative technologies and sustainable product development. The wide product range and custom synthesis services offer customers a tailored solution for their needs. Divi's Laboratories is a leading provider of active ingredients and has made a name for itself in the pharmaceutical and nutraceutical industry due to its high quality and productivity.

Divi's Laboratories SWOT Analysis

Strengths

  • Strong track record of research and development in the pharmaceutical industry.
  • Robust manufacturing capabilities and state-of-the-art facilities.

Weaknesses

  • Dependence on a limited number of key customers for a significant portion of revenue.
  • Vulnerability to changes in regulations or government policies.

Opportunities

  • Growing global demand for generic drugs presents expansion opportunities.
  • Increasing investments in R&D for innovative pharmaceutical products.

Threats

  • Intense competition from both domestic and international pharmaceutical companies.
  • Potential risks associated with intellectual property rights and patent infringement.

Divi's Laboratories Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Divi's Laboratories historical P/E ratio, EBIT multiple, and P/S ratio

Divi's Laboratories annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Divi's Laboratories shares outstanding

The number of shares of Divi's Laboratories was 265.47 M in 2025. This indicates how many shares Divi's Laboratories is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2021
265.00 M Stocks
Jan 1, 2022
265.00 M Stocks
Jan 1, 2023
265.47 M Stocks
Jan 1, 2024
265.47 M Stocks
Jan 1, 2025
265.47 M Stocks
Jan 1, 2026 (e)
265.47 M Stocks
Jan 1, 2027 (e)
265.47 M Stocks
Jan 1, 2028 (e)
265.47 M Stocks

Divi's Laboratories stock splits

In Divi's Laboratories's history, there have been no stock splits.

Divi's Laboratories Dividend History

23 years of dividend payments

YearAnnual DividendYoY ChangePayments
202530.00INR 0.0%1×
Jul 25, 202530.00INR 0.0%1/1
202430.00INR 0.0%1×
202330.00INR 0.0%1×
202230.00INR↑ 50.0%1×
202120.00INR↑ 25.0%1×
202016.00INR 0.0%1×
201916.00INR↑ 60.0%1×
201810.00INR 0.0%1×
201710.00INR 0.0%1×
201610.00INR↓ 50.0%1×

Divi's Laboratories dividend history and estimates

In 2025, Divi's Laboratories paid a dividend amounting to 30.00 INR. Dividend means that Divi's Laboratories distributes a portion of its profits to its owners.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Dividend
Dividend (Estimate)
Details
Date
Dividend
Dividend (Estimate)
Jan 1, 2021 (e)
0.00 INR
20.00 INR
Jan 1, 2022
30.00 INR
0.00 INR
Jan 1, 2023
30.00 INR
0.00 INR
Jan 1, 2024
30.00 INR
0.00 INR
Jan 1, 2025
30.00 INR
0.00 INR
Jan 1, 2026
30.00 INR
0.00 INR
Jan 1, 2027 (e)
0.00 INR
30.00 INR
Jan 1, 2028 (e)
0.00 INR
30.00 INR

Divi's Laboratories dividend payout ratio

In 2025, Divi's Laboratories had a payout ratio of 36.35%. The payout ratio indicates the percentage of the company's profits that Divi's Laboratories distributes as dividends.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Payout ratio
Details
Date
Payout ratio
Jan 1, 2021
26.71 %
Jan 1, 2022
26.86 %
Jan 1, 2023
43.68 %
Jan 1, 2024
49.78 %
Jan 1, 2025
36.35 %
Jan 1, 2026 (e)
30.72 %
Jan 1, 2027 (e)
25.83 %
Jan 1, 2028 (e)
21.01 %

Current Divi's Laboratories forecasts and price targets in August 2026

Analyst Price Targets 2026
Δ MOM Price Target
1.18 %
Buy
55.56 % (20)
Hold
16.67 % (6)
Sell
27.78 % (10)
12M Price Target
7,012.50
Last Price
8,457.00
Currency
INR
12M Return Potential
-17.08 %
LTM Return
0 %

Divi's Laboratories Earnings Estimates & Surprises

DateEPS estimateEPS ActualRevenue EstimatePrice reactionQuarterly report
5/18/202419.75INR-22.35 BINR-2024 Q4
2/1/202417.69INR-20.51 BINR-2024 Q3

EESG©

Eulerpool ESG Scorecard© for the Divi's Laboratories stock

77/100
88
Environment
90
Social
52
Governance
E

Environment

20
Scope 1 - Direct Emissions363,246
Scope 2 - Indirect emissions from purchased energy325,972
Scope 3 - Indirect emissions within the value chain—
Total CO₂ emissions689,218
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather—
Pesticides—
Palm Oil—
Tobacco
Genetically modified organisms
Climate concept—
Sustainable forestry—
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency
S

Social

20
Percentage of female employees9.792
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content
Alcohol
Weapons—
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept—
Occupational health and safety
Catholic
G

Governance (Corporate Governance)

4
Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Divi's Laboratories shareholder structure

% Name
20.34139%
Divi (Satchandra Kiran)
Divi (Satchandra Kiran)
20.34139%
Motaparti (Nilima)
Motaparti (Nilima)
5.27369%
Divi (Swarna Latha)
Divi (Swarna Latha)
4.55890%
SBI Funds Management Pvt. Ltd.
SBI Funds Management Pvt. Ltd.
3.54697%
GIC Private Limited
GIC Private Limited
3.01354%
Divis Biotech Pvt. Ltd.
Divis Biotech Pvt. Ltd.
...

Divi's Laboratories Beneficial Ownership Filings (SEC 13D/G)

Free Float
44.2%
Float Shares
-
Shares Outstanding
-

Divi's Laboratories Executives and Management Board

14 members · avg. age 66 · 14 % women

MD

Dr. Murali Divi (73)

Managing Director, Executive Director · since 2020

881.50 M INR

Management

KD

Dr. Kiran Divi (48)

Chief Executive Officer, Whole-Time Director · since 2020

307.70 M INR
LB

Mr. L. Kishore Babu (74)

Chief Financial Officer · since 2010

35.44 M INR
MC

Mr. Meka Satish Choudhury

Compliance Officer, Company Secretary

4.16 M INR
VP

Mr. Venkatesa Pasumarthy

Chief Financial Officer

–
MJ

Mr. Manoranjan Jasti

Chief Information Officer

–

Board of Directors

SR

Shri. Nimmagadda Ramana (66)

Executive Director · since 1994

451.80 M INR
ND

Ms. Nilima Divi

Whole-Time Director - (Commercial)

307.00 M INR
SR

Dr. Sureddy Rao

Whole-Time Director - (Manufacturing) · since 2024

31.10 M INR
RN

Dr. Ramesh Nimmagadda

Non-Executive Independent Chairman of the Board

3.50 M INR
SG

Dr. Seru Ganapaty (69)

Non-Executive Independent Director

3.20 M INR
SC

Shri. Kosaraju Chowdary

Non-Executive Independent Director

3.10 M INR

Frequently asked questions about Divi's Laboratories

The business model of Divi's Laboratories Ltd revolves around the manufacture and supply of active pharmaceutical ingredients (APIs) and intermediates to pharmaceutical companies worldwide. With a focus on quality, innovation, and cost-effective production, Divi's Labs caters to a wide range of therapeutic segments including generics, custom synthesis, and development of new molecules. By leveraging its strong research and development capabilities, cutting-edge technology, and state-of-the-art manufacturing facilities, Divi's Labs has established itself as a trusted supplier in the global pharmaceutical industry.

Divi's Laboratories Ltd is primarily active in the pharmaceutical industry.

The main competitors of Divi's Laboratories Ltd in the market include Sun Pharmaceutical Industries Ltd, Dr. Reddy's Laboratories Ltd, Lupin Ltd, and Cipla Ltd.

Divi's Laboratories Ltd is an Indian pharmaceutical company that was founded in 1990. It is headquartered in Hyderabad, Telangana. The company specializes in the research, development, and manufacturing of generic pharmaceuticals and active pharmaceutical ingredients (APIs). Divi's Laboratories has a strong focus on quality with a global customer base and is recognized for its state-of-the-art manufacturing facilities. Over the years, the company has consistently grown and expanded its product portfolio. Divi's Laboratories is committed to innovation, research, and delivering high-quality healthcare solutions to meet the needs of patients worldwide.

Divi's Laboratories Ltd has achieved numerous significant milestones throughout its journey. Notably, the company has consistently demonstrated excellence in the pharmaceutical sector since its establishment. Divi's Laboratories Ltd has successfully garnered a strong reputation for its high-quality manufacturing practices and commitment to innovation. The company has also gained several certifications, including ISO 9001, ISO 14001, and OHSAS 18001, further solidifying its credibility. Moreover, Divi's Laboratories Ltd has expanded its operations globally, establishing a strong presence in various international markets. These incredible achievements highlight Divi's Laboratories Ltd's unwavering dedication to delivering exceptional pharmaceutical solutions while maintaining the highest standards of quality and compliance.

Divi's Laboratories Ltd is primarily present in India, with its headquarters located in Hyderabad. The company operates multiple manufacturing facilities in different locations across India, including Visakhapatnam, Hyderabad, and Mahad. Divi's Laboratories Ltd focuses on manufacturing and supplying active pharmaceutical ingredients (APIs) and intermediates globally. It has a strong presence in various countries and regions, including the United States, Europe, Japan, Korea, and several emerging markets. With its commitment to quality and adherence to international regulatory standards, Divi's Laboratories Ltd has established itself as a trusted supplier of pharmaceutical products worldwide.

Divi's Laboratories Ltd is committed to upholding values of excellence, integrity, and innovation. With a strong corporate philosophy centered around quality and customer satisfaction, the company continually strives to provide top-notch pharmaceutical products and services. Divi's Laboratories Ltd focuses on research and development to ensure cutting-edge solutions and advancements in the field. The company's emphasis on ethical practices and transparency reflects its commitment to maintaining strong relationships with stakeholders. Divi's Laboratories Ltd's dedication to continuous improvement and market leadership makes it a preferred choice for investors seeking a reliable and progressive pharmaceutical company.

Analysts currently set an average price target of 6,987.18 INR for the Divi's Laboratories stock (median: 7,012.50 INR), implying -17.4 % versus the latest price. The consensus is based on 36 analyst ratings.

Divi's Laboratories Analyst Price Targets 2026

36 analysts currently rate the Divi's Laboratories stock: 21 recommend buying, 6 holding and 9 selling. For 2026, analysts expect Divi's Laboratories to generate revenue of 106.20 B INR and earnings per share of 97.66 INR.

Divi's Laboratories Analyst Price Targets 2026

Converted at the current exchange rate, the Divi's Laboratories share trades at 76.62 EUR (8,457.00 INR).

Divi's Laboratories Ltd is an Indian company that manufactures pharmaceutical active ingredients and intermediates for the global market. The company was founded in 1990 and is headquartered in Hyderabad, India. Divi's Laboratories' business model is based on extensive research and development and high production capacity. The company follows a vertically integrated production strategy, engaging in the development of new active ingredients and the production of intermediates and finished products. Divi's Laboratories serves a variety of industries such as the pharmaceutical and cosmetic industries, agriculture, and the food industry. The company offers a wide range of products such as antibiotics, antidepressants, vitamins, and folic acid for the pharmaceutical industry. For the cosmetic and food industries, the company offers emulsifiers, fragrances and flavors, as well as dyes and sunscreens. The company has two modern manufacturing facilities with a total capacity of over 500 tons per year. Divi's Laboratories continuously invests in state-of-the-art production facilities to increase capacity and productivity. Divi's Laboratories specializes in the manufacture of pharmaceutical active ingredients and intermediates and therefore enjoys a good reputation in the industry. The company has established a strong position in the market in recent years and has expanded into various countries such as the USA, Europe, and Asia. The company is also successful in research and development of new products. Divi's Laboratories has its own research and development department that develops new synthetic methods and processes for the production of active ingredients. The company works closely with customers to produce customized products for their specific requirements. Furthermore, Divi's Laboratories is involved in the research of natural substances that can be used in the medical field. The company has its own department for biotechnological research and development to isolate new natural substances and investigate their potential for medical application. In summary, Divi's Laboratories' business model is very successful and focused on a wide range of products and extensive research and development. The company has established a strong position in the global market for pharmaceutical active ingredients and intermediates and is on track to further expand its position.

The expected revenue of Divi's Laboratories is 106.20 B INR. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Divi's Laboratories is 25.92 B INR. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Divi's Laboratories is currently 86.60. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Divi's Laboratories stock.

The price-to-sales ratio (P/S) of Divi's Laboratories is currently 21.14. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Divi's Laboratories stock.

The Eulerpool Quality Score for Divi's Laboratories is 6/10.

The ISIN of Divi's Laboratories is INE361B01024. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Divi's Laboratories is DIVISLAB.NS. The ticker symbol is used to trade Divi's Laboratories shares on the stock exchange.

Over the past 12 months, Divi's Laboratories paid a dividend of 30.00 INR . This corresponds to a dividend yield of about 0.35 %. For the coming 12 months, Divi's Laboratories is expected to pay a dividend of 30.00 INR.

The current dividend yield of Divi's Laboratories is 0.35 %.

Divi's Laboratories pays a dividend, distributed in the months of , , , .

Divi's Laboratories paid dividends every year for the past 23 years.

For the upcoming 12 months, dividends amounting to 30.00 INR are expected. This corresponds to a dividend yield of 0.35 %.

Divi's Laboratories is assigned to the 'Health' sector.

To receive the latest dividend of Divi's Laboratories from amounting to 30 INR, you needed to have the stock in your portfolio before the ex-date on .

The last dividend was paid out on .

In the year 2025, Divi's Laboratories distributed 30 INR as dividends.

The dividends of Divi's Laboratories are distributed in INR.

All fundamentals and in-depth analysis of Divi's Laboratories

Our stock analysis for Divi's Laboratories stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Divi's Laboratories. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Divi's Laboratories Stock
Divi's Laboratories Revenue→
Divi's Laboratories Stock
Divi's Laboratories Net Income→
Divi's Laboratories Stock
Divi's Laboratories P/E→
Divi's Laboratories Stock
Divi's Laboratories P/S→
Divi's Laboratories Stock
Divi's Laboratories EBIT→
Divi's Laboratories Stock
Divi's Laboratories Dividend→
Divi's Laboratories Stock
Divi's Laboratories Directors Dealings→
Divi's Laboratories Stock
Divi's Laboratories Stocks→
Divi's Laboratories Stock
Divi's Laboratories Market capitalization→
Divi's Laboratories Stock
Divi's Laboratories Debt→
Divi's Laboratories Stock
Divi's Laboratories Liabilities→
Divi's Laboratories Stock
Divi's Laboratories Equity→
Divi's Laboratories Stock
Divi's Laboratories AAQS→
Divi's Laboratories Stock
Divi's Laboratories Employees→
Divi's Laboratories Stock
Divi's Laboratories ROE→
Divi's Laboratories Stock
Divi's Laboratories ROA→
Divi's Laboratories Stock
Divi's Laboratories ROCE→
Divi's Laboratories Stock
Divi's Laboratories News→
Divi's Laboratories Stock
Divi's Laboratories Analyst Price Targets→

Health Stocks

Dizal Pharmaceutical CoDishman Carbogen AmcisDNAPrint GenomicsDisc MedicineDocCheckDirui Industrial CoDocGoDipna PharmachemDocMode Health TechnologiesDioDoctorglasses Chain CoDimerixAll Stocks A–Z →